GLP-3 (Retatrutide) 30mg – Research-Grade Triple Agonist Peptide for Metabolic & GLP Receptor Studies
Buy
GLP-3 (Retatrutide) 30mg at Peppy University, a premium research-grade triple agonist peptide used for
laboratory studies on GLP-1 receptor activity, GIP receptor signaling, glucagon receptor pathways, and advanced metabolic regulation. GLP-3 is the research name for
Retatrutide — the next-generation GLP peptide studied beyond semaglutide and tirzepatide, targeting three metabolic receptors simultaneously.
Where semaglutide targets GLP-1 only and tirzepatide targets GLP-1 + GIP,
Retatrutide (GLP-3) adds the glucagon receptor — the third target — which increases energy expenditure and drives hepatic fat oxidation in preclinical models. Phase 2 trial data published in JAMA showed Retatrutide produced mean body weight reduction of
24.2% at 48 weeks — surpassing both semaglutide (~15%) and tirzepatide (~20%) in metabolic endpoints.
What is Retatrutide (GLP-3)?
Retatrutide is a synthetic triple agonist peptide developed by Eli Lilly, currently in Phase 3 TRIUMPH trials as of 2026. In preclinical and Phase 2 research, it has been studied for its effects on:
- GLP-1 receptor activation — insulin secretion, appetite suppression, and gastric motility
- GIP receptor activation — enhanced insulin response and adipose tissue signaling
- Glucagon receptor activation — increased energy expenditure and hepatic fat oxidation
GLP-3 in Preclinical Research
- Triple receptor agonism — Retatrutide simultaneously activates GLP-1, GIP, and glucagon receptors, offering a broader metabolic research profile than dual or single agonists.
- Body composition studies — Phase 2 data showed continuous weight loss through 48 weeks with no plateau observed, making it a compelling subject for obesity and metabolic research models.
- Glucose metabolism — Research has examined Retatrutide’s effects on fasting glucose, postprandial glucose, and HbA1c in metabolic dysfunction models.
- Hepatic fat reduction — The glucagon component drives hepatic fat oxidation pathways not activated by GLP-1 alone, relevant to NAFLD research models.
- Cardiovascular research — Studies are exploring GLP-1/GIP/glucagon receptor signaling in cardiac tissue and cardioprotective mechanisms.
GLP-3 vs Semaglutide vs Tirzepatide
- Semaglutide — GLP-1 agonist only (~15% weight reduction in trials)
- Tirzepatide — GLP-1 + GIP dual agonist (~20% weight reduction in trials)
- GLP-3 (Retatrutide) — GLP-1 + GIP + Glucagon triple agonist (~24.2% weight reduction in Phase 2)
Molecular Profile
- Form: Lyophilized powder
- Purity: 99% (HPLC verified)
- Storage: -20°C, protected from light and moisture
- Reconstitution: Bacteriostatic water or sterile saline
Key Benefits for Research
- Supports triple receptor metabolic research — GLP-1, GIP, and glucagon pathways in one compound
- Enables next-generation GLP studies beyond semaglutide and tirzepatide protocols
- Lab-tested, high-purity peptide for consistent and reproducible results
- Comes with scientific documentation for research compliance
Ideal for
scientific research, laboratory experiments, and advanced metabolism-focused peptide studies, GLP-3 (Retatrutide) ensures
reliable outcomes for researchers requiring
high-quality, reproducible results.
Order now from Peppy University for secure delivery and fast shipping.
